With over two decades of experience at the intersection of biotechnology, healthcare, and wellness, Doug Chloupek is a pioneering entrepreneur committed to advancing solutions for health and longevity. As the Founder and CEO of Azalla Longevity LLC, Doug leads a visionary company focused on pharmaceutical innovation, wellness programs, and consumer products that promote long and healthy lives. Under Doug’s leadership, Azalla is redefining the wellness industry through science-driven solutions and strategic integration across its business entities.

Sanjeev has an extensive track record of discovering and developing pharmaceutical drug candidates. Prior to joining Juva, he served as Director of Oncology Discovery Chemistry for Bristol-Myers Squibb, a global biopharma company, where he successfully discovered and developed novel classes of cancer therapeutics. In his career spanning 25 years, Sanjeev has focused on oncology and immuno-oncology research and held R&D leadership roles in several biopharmaceutical companies. He earned his Ph.D. in Organic Chemistry/Natural products at the University of Arizona and completed his postdoctoral training in Medicinal Chemistry at the University of Kansas. Sanjeev is co-inventor of 45 patents, has co-authored over 40 peer-reviewed papers and has presented his work at numerous international conferences.

Guy Miller, MD, Ph.D. directs our science advisory board. In this capacity, he is responsible for synthesizing our business and technical strategy into a cohered R/D plan, and working with our internal team and external experts to drive corporate objectives. Dr. Miller holds both a Ph.D. in chemistry and an MD, completing his training at the University of Chicago and Johns Hopkins School of Medicine. He is currently the founder and CEO of Emerja Corporation, chairman of the board of directors, Pneumico, Inc. and an adjunct faculty member at Johns Hopkins School of Medicine, Department of Anesthesiology and Critical Care Medicine. He possesses broad expertise in natural products pharmacology, drug development, and innovation.

Dr. Beitsch went to medical school at University of Texas Southwestern Medical School in Dallas and finished his general surgery residency at Parkland Hospital in Dallas in 1993. He had a National Cancer Institute fellowship at M.D. Anderson Cancer Center from 1988-90. He completed his training with a surgical oncology fellowship at the John Wayne Cancer Institute in Santa Monica, California. In 1994, he returned to private practice in Dallas where his practice is focused on melanoma and breast cancer.
He has held numerous positions in national surgical societies including the American Society of Breast Surgeons where he served as President of the Society from 2013-14, first Chairman of the Membership Committee 2001-4, Program Director for the 2005 Annual Meeting in Los Angeles, Board of Directors Member from 2006-9 and 2012-15. He has served on the Executive Committee of the Society of Surgical Oncology 2008-2010, General Surgical Oncology Committee of the American Board of Surgery and was a National Ultrasound Faculty for the American College of Surgeons.
Dr. Beitsch has given numerous national and international presentations and is actively involved in breast cancer and melanoma research. He has major articles in peer-reviewed medical journals including the New England Journal of Medicine, the Journal of the American Medical Association, the Proceedings of the National Academy of Science, Journal of Clinical Oncology, and the Annals of Surgical Oncology.

A renowned Oncologist and clinical researcher in the San Francisco Bay Area, with over 150 worldwide lectures and 100 publications to-date, Dr. Patel is also a seasoned entrepreneur with multiple healthcare start-ups. He is currently practicing in the Bay Area with Precision Cancer Specialists Medical Group.

Mary Kay spent her years working in business and product development before moving into research for a series of early stage medical device and diagnostic companies. Mary Kay is also an advocate for cancer patients and caregivers via a number of organizations.